Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551
Authors:
Monika Joshi
Leonard Tuanquin
Junjia Zhu
Vonn Walter
Todd D. Schell
Matthew Kaag
Deepak Kilari
Jiangang Liao
Sheldon L. Holder
Hamid Emamekhoo
Alexander Sankin
Suzzane Merrill
Hong Zheng
Joshua Warrick
Ralph J. Hauke
Benjamin Gartrel
Mark N. Stein
Joseph J. Drabick
David J. DeGraff
Yousef Zakharia
Affiliated Authors:
Mark N. Stein
Author Keywords:
immunotherapy
radioimmunotherapy
urinary bladder neoplasms
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-006551
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: